US Pharma MarketingStruggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI
Struggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI.
Source: FierceBiotech